Immuneering Corp
NASDAQ:IMRX
Balance Sheet
Balance Sheet Decomposition
Immuneering Corp
Current Assets | 89.1m |
Cash & Short-Term Investments | 85.7m |
Other Current Assets | 3.4m |
Non-Current Assets | 13.5m |
PP&E | 5.4m |
Intangibles | 7.1m |
Other Non-Current Assets | 1m |
Current Liabilities | 7.8m |
Accounts Payable | 2.1m |
Accrued Liabilities | 5.5m |
Other Current Liabilities | 259.8k |
Non-Current Liabilities | 4.2m |
Other Non-Current Liabilities | 4.2m |
Balance Sheet
Immuneering Corp
Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
---|---|---|---|---|---|---|
Assets | ||||||
Cash & Cash Equivalents |
14
|
37
|
75
|
73
|
59
|
|
Cash Equivalents |
14
|
37
|
75
|
73
|
59
|
|
Short-Term Investments |
0
|
0
|
74
|
33
|
26
|
|
Total Receivables |
0
|
1
|
0
|
0
|
0
|
|
Accounts Receivables |
0
|
1
|
0
|
0
|
0
|
|
Other Receivables |
0
|
0
|
0
|
0
|
0
|
|
Other Current Assets |
0
|
0
|
3
|
3
|
3
|
|
Total Current Assets |
14
|
38
|
152
|
109
|
89
|
|
PP&E Net |
0
|
1
|
6
|
6
|
5
|
|
PP&E Gross |
0
|
1
|
6
|
6
|
5
|
|
Accumulated Depreciation |
0
|
0
|
0
|
0
|
1
|
|
Intangible Assets |
0
|
0
|
0
|
0
|
0
|
|
Goodwill |
0
|
0
|
7
|
7
|
7
|
|
Long-Term Investments |
0
|
0
|
1
|
0
|
0
|
|
Other Long-Term Assets |
0
|
0
|
0
|
1
|
1
|
|
Other Assets |
0
|
0
|
7
|
7
|
7
|
|
Total Assets |
14
N/A
|
38
+172%
|
167
+334%
|
122
-27%
|
103
-16%
|
|
Liabilities | ||||||
Accounts Payable |
0
|
2
|
1
|
3
|
2
|
|
Accrued Liabilities |
0
|
1
|
4
|
5
|
5
|
|
Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
|
Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
|
Total Current Liabilities |
1
|
2
|
6
|
8
|
8
|
|
Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
|
Other Liabilities |
4
|
1
|
5
|
5
|
4
|
|
Total Liabilities |
4
N/A
|
3
-30%
|
11
+282%
|
13
+17%
|
12
-4%
|
|
Equity | ||||||
Common Stock |
17
|
58
|
0
|
0
|
0
|
|
Retained Earnings |
9
|
26
|
59
|
110
|
163
|
|
Additional Paid In Capital |
2
|
3
|
215
|
220
|
254
|
|
Other Equity |
0
|
0
|
0
|
0
|
0
|
|
Total Equity |
10
N/A
|
36
+252%
|
156
+338%
|
110
-30%
|
91
-18%
|
|
Total Liabilities & Equity |
14
N/A
|
38
+172%
|
167
+334%
|
122
-27%
|
103
-16%
|
|
Shares Outstanding | ||||||
Common Shares Outstanding |
24
|
24
|
26
|
26
|
29
|